Published in Oncogene on September 04, 2006
Molecular mechanisms of cancer development in obesity. Nat Rev Cancer (2011) 3.65
Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res (2010) 1.70
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol (2010) 1.61
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48
Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell (2012) 1.44
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38
Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr (2011) 1.26
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res (2010) 1.20
The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer (2015) 1.05
Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat (2011) 1.04
Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development. Dev Biol (2007) 1.04
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem (2011) 1.03
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res (2008) 1.01
Insulin-like growth factor type 1 receptor and insulin receptor isoform expression and signaling in mammary epithelial cells. Endocrinology (2009) 0.98
BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res (2009) 0.97
PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer. PPAR Res (2009) 0.96
Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models. Breast Cancer Res (2008) 0.93
Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog (2012) 0.92
Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women. Growth Horm IGF Res (2010) 0.92
IGF ligand and receptor regulation of mammary development. J Mammary Gland Biol Neoplasia (2008) 0.92
A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells. Mol Cancer Res (2008) 0.90
Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature. Oncogene (2011) 0.87
Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment. Am J Pathol (2011) 0.87
Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res (2009) 0.87
Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer (2010) 0.86
Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity. J Cell Biochem (2012) 0.85
Type I insulin-like growth factor receptor induces pulmonary tumorigenesis. Neoplasia (2009) 0.84
Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice. BMC Cancer (2013) 0.84
Murine mammary tumor cells with a claudin-low genotype. Cancer Cell Int (2011) 0.84
Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors. BMC Cancer (2011) 0.83
LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis. Mol Cancer (2011) 0.83
ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis. Mol Cancer (2010) 0.82
IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. Cancer Res (2014) 0.80
Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES. Exp Mol Pathol (2010) 0.79
Caveolin-1 expression is elevated in claudin-low mammary tumor cells. Cancer Cell Int (2012) 0.79
Small molecule inhibitors of IRES-mediated translation. Cancer Biol Ther (2015) 0.78
Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells. Mol Cell Endocrinol (2012) 0.78
Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis. Oncotarget (2016) 0.78
The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics (2013) 0.78
BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes (2016) 0.77
High levels of dietary soy decrease mammary tumor latency and increase incidence in MTB-IGFIR transgenic mice. BMC Cancer (2015) 0.76
miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev (2017) 0.75
IGF-IR mediated mammary tumorigenesis is enhanced during pubertal development. PLoS One (2014) 0.75
Insulin-like growth factor-1 signaling in renal cell carcinoma. BMC Cancer (2016) 0.75
Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells. BMC Cancer (2016) 0.75
Metformin targets multiple signaling pathways in cancer. Chin J Cancer (2017) 0.75
Re-expression of miR-200c suppresses proliferation, colony formation and in vivo tumor growth of murine claudin-low mammary tumor cells. Oncotarget (2017) 0.75
An RNA polymerase II transcription factor binds to an upstream element in the adenovirus major late promoter. Cell (1985) 10.06
A single polypeptide possesses the binding and transcription activities of the adenovirus major late transcription factor. Mol Cell Biol (1986) 7.49
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene (1998) 4.88
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med (2001) 3.51
Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med (2000) 2.61
Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev (2001) 2.35
Precocious mammary gland development in P-cadherin-deficient mice. J Cell Biol (1997) 2.10
The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet (1995) 2.02
Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem (1994) 1.99
The major late transcription factor binds to and activates the mouse metallothionein I promoter. Genes Dev (1987) 1.94
Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature (2000) 1.93
Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest (2001) 1.78
Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest (2001) 1.71
Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci U S A (1996) 1.70
Targeted mutagenesis of DNA using triple helix-forming oligonucleotides linked to psoralen. Proc Natl Acad Sci U S A (1993) 1.69
Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev (1995) 1.66
Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle. Biol Reprod (2001) 1.63
Timp-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development. Dev Biol (1999) 1.63
Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med (2003) 1.54
Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res (1995) 1.52
Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett (1997) 1.36
Developmental expression of Brca2 colocalizes with Brca1 and is associated with proliferation and differentiation in multiple tissues. Dev Biol (1997) 1.32
Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer (2003) 1.30
Tissue inhibitor of metalloproteinases-3 facilitates Fas-mediated neuronal cell death following mild ischemia. Cell Death Differ (2007) 1.26
Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc Natl Acad Sci U S A (1996) 1.25
Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res (1994) 1.23
MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and up-regulation of cadherin function. J Biol Chem (2001) 1.23
Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis (2003) 1.22
Sp1, a CAAT-binding factor, and the adenovirus major late promoter transcription factor interact with functional regions of the gamma-fibrinogen promoter. Mol Cell Biol (1988) 1.21
Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res (2001) 1.21
Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci. Mol Cell Biol (2001) 1.17
The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene (2010) 1.15
Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol (1999) 1.11
Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene (2010) 1.09
Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: characterization of psoralen monoadduct and crosslink formation. Nucleic Acids Res (1994) 1.09
Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol (2000) 1.09
Cellular turnover and extracellular matrix remodeling in female reproductive tissues: functions of metalloproteinases and their inhibitors. Cell Mol Life Sci (2000) 1.08
Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene (1996) 1.08
Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol (1999) 1.08
Characterization of adjacent breast tumors using oligonucleotide microarrays. Breast Cancer Res (2001) 1.06
Reversibility and recurrence of IGF-IR-induced mammary tumors. Oncogene (2009) 1.05
Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood (1997) 1.04
Fetal and neonatal exposure to nicotine in Wistar rats results in increased beta cell apoptosis at birth and postnatal endocrine and metabolic changes associated with type 2 diabetes. Diabetologia (2005) 1.04
Developmental role of the SNF1-related kinase Hunk in pregnancy-induced changes in the mammary gland. Development (2000) 1.03
Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice. Cell Death Differ (2001) 1.02
Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp-3-/- mice. Oncogene (2006) 1.00
Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene (1998) 1.00
Cloning and characterization of Hunk, a novel mammalian SNF1-related protein kinase. Genomics (2000) 0.99
The bacterial lacZ gene: an important tool for metastasis research and evaluation of new cancer therapies. Cancer Metastasis Rev (1999) 0.99
Extracellular matrix proteins and tumor angiogenesis. J Oncol (2010) 0.97
TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene (2006) 0.93
Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis (2000) 0.93
Temporal and spatial expression of tissue inhibitors of metalloproteinases during the natural ovulatory cycle of the mouse. Biol Reprod (1996) 0.93
Mobility shift DNA-binding assay using gel electrophoresis. Curr Protoc Mol Biol (2001) 0.93
Effects of the disintegrin eristostatin on individual steps of hematogenous metastasis. Exp Cell Res (1995) 0.92
Frequent spontaneous deletions at a shuttle vector locus in transgenic mice. Mutagenesis (1996) 0.92
Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab Invest (1999) 0.91
Modulation of translation by the 5' leader sequence of the mRNA encoding murine tissue inhibitor of metalloproteinases. J Biol Chem (1990) 0.90
Fetal and neonatal exposure to nicotine disrupts ovarian function and fertility in adult female rats. Endocrine (2006) 0.90
DNA transfer of focus- and tumor-forming ability into nontumorigenic CHEF cells. Proc Natl Acad Sci U S A (1982) 0.88
cAMP response element-binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation. Int J Gynecol Cancer (2008) 0.88
Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature. Oncogene (2011) 0.87
Cloning, characterization, and chromosomal localization of Pnck, a Ca(2+)/calmodulin-dependent protein kinase. Genomics (2000) 0.86
The caM kinase, Pnck, is spatially and temporally regulated during murine mammary gland development and may identify an epithelial cell subtype involved in breast cancer. Cancer Res (2000) 0.86
Cloning and characterization of Krct, a member of a novel subfamily of serine/threonine kinases. Hum Mol Genet (1998) 0.85
The role of dysregulated glucose metabolism in epithelial ovarian cancer. J Oncol (2010) 0.84
Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. Diabetes Obes Metab (2007) 0.84
Back to basics: iatrogenic intravenous cannula embolus. Ann R Coll Surg Engl (2013) 0.83
Antisense down-regulation of metallothionein in a human monocytic cell line alters adherence, invasion, and the respiratory burst. Cell Growth Differ (1994) 0.83
Relationships between ultrasonographic image attributes, histomorphology and proliferating cell nuclear antigen expression of bovine antral follicles and corpora lutea ex situ. Reprod Domest Anim (2008) 0.82
Different patterns of gene expression in ras-resistant and ras-sensitive cells. J Natl Cancer Inst (1991) 0.81
Genetic background influences timing, morphology and dissemination of lymphomas in p53-deficient mice. Int J Oncol (1998) 0.81
Temporal expression of tissue inhibitors of metalloproteinases in mouse reproductive tissues during gestation. Mol Reprod Dev (1993) 0.81
Inhibition of VLA-4 and up-regulation of TIMP-1 expression in B16BL6 melanoma cells transfected with MHC class I genes. Clin Exp Metastasis (1998) 0.80
Divergent effects of d-norgestrel on the metabolism of rat very low density and low density apolipoprotein B. J Lipid Res (1986) 0.80
Characterization of a mouse mitogen-regulated protein/proliferin gene and its promoter: a member of the growth hormone/prolactin gene superfamily. Biochim Biophys Acta (1989) 0.80
Play ball! Science (1995) 0.79
Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo. J Natl Cancer Inst (1989) 0.79
Effects of levonorgestrel on enzymes responsible for synthesis of triacylglycerols in rat liver. Biochim Biophys Acta (1987) 0.79
Oncogenic consequences of down-modulating TIMP expression in 3T3 cells with antisense RNA. Matrix Suppl (1992) 0.79
Hypotriglyceridemic effects of levonorgestrel in rats. Atherosclerosis (1984) 0.79
Analysis of murine Brca2 reveals conservation of protein-protein interactions but differences in nuclear localization signals. J Biol Chem (2001) 0.78
Targeted mutagenesis mediated by the triple helix formation. Methods Mol Biol (1996) 0.78
Influence of dichlorodiphenylchloroethylene on vascular endothelial growth factor and insulin-like growth factor in human and rat ovarian cells. Reprod Toxicol (2007) 0.77
Low levels of X-inactive specific transcript in somatic cell nuclear transfer embryos derived from female bovine freemartin donor cells. Sex Dev (2011) 0.77
Lactate detection in inducible and orthotopic Her2/neu mammary gland tumours in mouse models. NMR Biomed (2012) 0.76
Mobility shift DNA-binding assay using gel electrophoresis. Curr Protoc Pharmacol (2001) 0.76
Preneoplastic changes persist after IGF-IR downregulation and tumor regression. Oncogene (2010) 0.76